After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
The company will lay off over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&D workforce), including changes to the leadership team.On Thursday, Sage Therapeutics, Inc. (NASDAQ:SAGE) announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) in postpartum depression.
週四，Sage Therapeutics, Inc.（納斯達克：SAGE）宣佈戰略性重新組織其業務以支持Zurzuvae（zuranolone）在產後抑鬱症的持續推出。
The reorganization is intended to enable Sage to strengthen its balance sheet, extend its cash runway, and position the company for long-term growth potential.
該重新組織旨在使Sage加強其資產負債表，延長現金儲備，爲公司開展業務鋪平長期增長潛力的道路。
The reorganization is planned to be substantially completed by the end of the fourth quarter of 2024.
該重新組織計劃於2024年第四季度結束前基本完成。
The company will lay off over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&D workforce), including changes to the leadership team.
該公司將裁員165多名員工（約佔其總員工數的33%，研發員工的約55%），包括領導團隊的調整。
Sage expects a non-recurring charge of approximately $26 million to $28 million associated with the reorganization.
Sage預計在重新組織中產生約2600萬至2800萬美元的一次性費用。
The company anticipates that implementing the restructuring will extend its cash runway. Sage will also implement early-stage pipeline prioritization.
公司預計通過實施重組來延長其現金儲備。Sage還將實施早期階段的管線優先。
The company will focus its pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington's Disease, which is expected later this year.
該公司將把管線開發工作集中在Huntington病（Huntington's Disease）的dalzanemdor臨床研究披露前，這個報道預計將在今年晚些時候進行。
In July, Sage and Biogen Inc (NASDAQ:BIIB) announced to close the ongoing open-label safety study of SAGE-324 in essential tremor and do not plan to conduct further clinical development of SAGE-324 in essential tremor.
在7月，Sage與Biogen Inc（納斯達克：BIIB）宣佈將關閉SAGE-324在重要性震顫中正在進行的無標籤安全研究，並不計劃在重要性震顫中進一步開展SAGE-324的臨床開發。
The KINETIC 2 study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score.
KINETIC 2研究未能證明基線到第91天的變化在主要終點上存在統計學顯著的劑量-反應關係，關鍵性震顫評估量表（TETRAS）表現子量表（PS）第4項（上肢）總分。
In September, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the SAGE-324 program.
渤健公司在九月份終止了與Sage的合作和許可協議下的權利，該協議專門針對SAGE-324項目。
Last week, Sage pulled a plug on the further clinical development of dalzanemdor in Alzheimer's after the LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the study's primary outcome measure.
上週，Sage在LIGHTWAVE研究中對達爾莎內多爾在治療阿爾茨海默病患者中的表現與安慰劑相比在第84天的韋氏成人智力量表第四版（WAIS-IV）編碼測試得分上未能顯示出統計學顯著差異之後，取消了對達爾莎內多爾進一步臨床發展的計劃，該研究的主要結果測量項目。
Price Action: SAGE stock is down 4.81% at $6.92 at last check Thursday.
價格走勢：SAGE股價上週四最後一次查看時下跌4.81%，爲6.92美元。
- ShiftPixy's Big AI Move: Supercharges Workforce Management With $150M TurboScale Deal.
- shiftpixy的重大人工智能舉措：通過15000萬美元的TurboScale交易爲勞動力管理注入動力。
譯文內容由第三人軟體翻譯。
